When evaluating a potential merger or acquisition candidate a wealth of many considerations need to be taken into account to arrive at a partner of best "fit".
Companies may have similar products in their portfolios that strengthen the merged company or they may present a competitive threat. Either way, a global understanding of their business is required to fully understand the commericial opportunity. In doing so a complete picture of the major brands, their therapeutic classes, and the geographical spread of the business must be developed. A sales breakdown will then reveal where the fit is advantageous and where weaknesses exist.
An evaluated analysis on how the company measures up at three critical stages of the product lifecycle; its ability to innovate, launch drugs and protect its intellectual property, give a further dimension to the suitability as an M&A target. Understanding the candidate's overall strategy, and its fit with the acquiring company, is vital research in the case for the acquisition. With this information, decision makers are better positioned to examine the potential new corporate entity and determine its potential market share, and ranking amongst the competition.